Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095529 | 1.00 | ENPP2 (0.46) | ENPP2GLAGSK3BMEN1KMT2A | |
| SCHEMBL30583447 | 1.00 | ENPP2 (0.46) | ENPP2GLAGSK3BMEN1KMT2A | |
| SCHEMBL29857813 | 1.00 | ENPP2 (0.46) | ENPP2GLAGSK3BMEN1KMT2A | |
| SCHEMBL214901 | 1.00 | ENPP2 (0.46) | ENPP2GLAGSK3BMEN1KMT2A | |
| SCHEMBL1022809 | 0.86 | ENPP2 (0.44) | ENPP2GLAGSK3BADRA1DADRA1A | |
| SCHEMBL11601220 | 0.83 | ENPP2 (0.48) | ENPP2GSK3BMEN1KMT2AADRA1D | |
| SCHEMBL4693798 | 0.83 | ENPP2 (0.48) | ENPP2GSK3BMEN1KMT2AADRA1D | |
| SCHEMBL104898 | 0.83 | GLA (0.46) | ENPP2GLAGSK3BADRA1DADRA1A | |
| SCHEMBL27475654 | 0.82 | GSK3B (0.46) | ENPP2GLAGSK3BADRA1DADRA1A | |
| SCHEMBL15617615 | 0.82 | ESR1 (0.44) | ENPP2GLAGSK3BADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033454-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024018423-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2024-01-25 | — | — | WO | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2009005687-A1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1915338-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1869055-A1 | NOVEL 5,7-DISUBSTITUTED Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDIN-2(3H)-ONE DERIVATIVES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006107257-A1 | NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| CN-1344270-A | Functionalized heterocycles as chemokine receptor modulators | THOUSAND YEARS MEDICAMENTS INC (US) | 2002-04-10 | — | — | CN | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | ENPP2 1859/4885GLA 2677/4885GSK3B 3606/4885 |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | ENPP2 1223/4885GLA 3993/4885GSK3B 713/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | ENPP2 1948/4885GLA 4500/4885GSK3B 3105/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | ENPP2 4075/4885GLA 2830/4885GSK3B 2851/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | ENPP2 3468/4885GLA 3687/4885GSK3B 2014/4885 |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | ENPP2 236/4885GLA 3845/4885GSK3B 2844/4885 |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | ENPP2 376/4885GLA 3058/4885GSK3B 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.